Plain-English translation of NCT06793670 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called , which is a fast-acting beta-blocker, to see if it can better protect your heart during mitral valve surgery. The medication is given through an IV during the operation to reduce your heart's stress and oxygen needs while it's not beating normally. Researchers want to know if this approach can lower the risk of serious complications after surgery, like heart failure and irregular heartbeats.
After heart valve surgery, some patients—especially those at higher risk—develop a dangerous condition where the heart cannot pump enough blood, which can lead to prolonged hospital stays and serious outcomes. This trial is exploring whether giving this medication during surgery can prevent that complication by better protecting the heart during the operation.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the study medication or a placebo (salt water) during your mitral valve surgery. The medication or placebo is given through an IV in three doses: a slow infusion before the surgeon clamps the main artery, then two bolus injections at specific points during the operation. After surgery, you will be monitored in the hospital as usual, and the research team will track your recovery and any complications over the following year.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Italy